Navigation Links
China Nuvo Solar Energy, Inc. Completes Name Change to SurgLine International, Inc.
Date:1/26/2012

WEST PALM BEACH, Fla., Jan. 26, 2012 /PRNewswire/ -- China Nuvo Solar Energy, Inc., (OTCQB: CNUV) today announced the company's official name change to SurgLine International, Inc. has been completed and approved by FINRA. The Company will commence trading under the new OTC ticker symbol: SGLN, effective tomorrow, January 27, 2012. SurgLine, Inc. ("SurgLine") remains the wholly owned operating subsidiary of SGLN.

Thomas Toland, CEO of SGLN and SurgLine, stated, "We are very pleased that we have concluded being able to change the name of our public entity to SurgLine International, Inc., as it more accurately describes our core business of SurgLine. We also believe that it gives us the proper organizational structure to carry out not only our current plans, but our long term corporate strategy of building shareholder value."

About SurgLine, Inc.

SurgLine (www.surgline.com) sources and distributes high quality FDA approved medical and surgical products at discount prices, thereby reducing or eliminating the historical brand premium paid by healthcare providers including acute care hospitals, surgery centers, surgical hospital, self insured employers and insurance companies. SurgLine offers high quality medical and surgical supplies and products at substantial savings utilizing stocking distributors and institutional buyers by sourcing products globally without the historical brand premium and industry markup.

About SurgLine International, Inc.

SurgLine International, Inc. is a holding company that in addition to SurgLine, wholly owns Nuvo Solar Energy, Inc., a development stage company that owns unique patent pending solar and photovoltaic related technology.  The Company is also seeking other business opportunities.

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.

For Further Information Contact:
Thomas Toland
949-698-8485

 


'/>"/>
SOURCE China Nuvo Solar Energy, Inc.; SurgLine International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price ... in the global Autism Spectrum Disorder market. The research answers ... key drugs marketed for Autism Spectrum Disorder and their clinical attributes? ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... 23, 2017 , ... On April 13, 2017, The ... “Doping in Sport: How the Culture Might Change,” in conjunction with Pepperdine ... will be held at Pepperdine University in Malibu, California. , Sir Philip Craven, ...
Breaking Medicine News(10 mins):